Precigen
Precigen is a US-based biotechnology company that leads 2 cancer trials in OnCo, testing the adenoviral immunotherapies PRGN-2012 (Papzimeos) and PRGN-2009 in rare cancers of childhood and cervical cancer.
Overview
Precigen is a commercial-stage biopharmaceutical company developing precision medicines for difficult-to-treat diseases. Its first approved product, Papzimeos (zopapogene imadenovec, formerly PRGN-2012), is an adenoviral immunotherapy for recurrent respiratory papillomatosis; PRGN-2009 for HPV-associated cancers and the UltraCAR-T programmes are in phase 1. On ClinicalTrials.gov it is the lead sponsor of 2 trials recorded in OnCo: NCT04724980 (phase 1/2, Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis) and NCT06157151 (phase 2, PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Ce...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Scorecard
All companies- approved products +6
- targets +2
- modalities +2
- regions +6
- 24-month regulatory events +6
- registry trials +30
Similar pages
not linked directly; found by shared links- CancerNasal cavity and paranasal sinus cancers (including esthesioneuroblastoma)
Shares Rare cancers of childhood (NCI PDQ umbrella), Pembrolizumab.
- CancerAdrenocortical carcinoma
Shares Rare cancers of childhood (NCI PDQ umbrella), Pembrolizumab.
- TreatmentNonavalent HPV vaccine
Shares Rare cancers of childhood (NCI PDQ umbrella), Cervical cancer.